Trespalacios Fernando C, Taylor Allen J, Agodoa Lawrence Y, Bakris George L, Abbott Kevin C
Nephrology Service, Madigan Army Medical Center, Ft Lewis, Washington, DC, USA.
Am J Kidney Dis. 2003 Jun;41(6):1267-77. doi: 10.1016/s0272-6386(03)00359-7.
Risk factors for heart failure (HF) have not been reported previously in a nationally representative sample of dialysis patients.
We conducted a historic cohort study of 1,995 patients enrolled in the US Renal Data System Dialysis Morbidity and Mortality Study Wave 2 who were Medicare eligible at the study start and were followed up until December 31, 1999, or receipt of a renal transplant. Cox regression analysis was used to model associations with time to first hospitalization for both recurrent and de novo HF (International Classification of Diseases, Ninth Revision code 428.x), defined as patients with and without a history of HF, respectively.
The incidence density of HF was 71/1,000 person-years. Angiotensin-converting enzyme inhibitors and beta-blockers were each used in less than 25% of patients with a known history of HF. A history of coronary heart disease was associated with an increased total risk for HF, as were hemodialysis (versus peritoneal dialysis), aspirin use, and a history of diabetes. However, hemodialysis and aspirin use were the only factors associated with both de novo and recurrent HF. Widened pulse pressure was associated with de novo HF. The mortality rate after HF was 83% at 3 years (adjusted hazard ratio for mortality, 2.10; 95% confidence interval, 1.80 to 2.45; P < 0.0001).
In chronic dialysis patients, hemodialysis and aspirin use were associated with increased risk for both total and de novo HF. Hospitalized HF was associated with a significantly increased risk for death.
此前尚未在具有全国代表性的透析患者样本中报告心力衰竭(HF)的危险因素。
我们对1995名参加美国肾脏数据系统透析发病率和死亡率研究第2波的患者进行了一项历史性队列研究,这些患者在研究开始时符合医疗保险资格,并随访至1999年12月31日或接受肾移植。采用Cox回归分析对复发性和新发HF首次住院时间的关联进行建模(国际疾病分类第九版代码428.x),分别定义为有和无HF病史的患者。
HF的发病密度为71/1000人年。已知有HF病史的患者中,使用血管紧张素转换酶抑制剂和β受体阻滞剂的患者均不到25%。冠心病史与HF的总风险增加相关,血液透析(与腹膜透析相比)、使用阿司匹林和糖尿病史也与HF的总风险增加相关。然而,血液透析和使用阿司匹林是与新发和复发性HF均相关的唯一因素。脉压增宽与新发HF相关。HF后3年的死亡率为83%(死亡率的调整风险比为2.10;95%置信区间为1.80至2.45;P<0.0001)。
在慢性透析患者中,血液透析和使用阿司匹林与HF的总风险和新发风险增加相关。住院HF与死亡风险显著增加相关。